Cyclopharm Ltd.

Sydney, Australia

Cyclopharm Ltd.

Sydney, Australia
SEARCH FILTERS
Time filter
Source Type

— The report titled “Pulmonary Embolism Diagnostic Market: Size, Trends & Forecasts (2017-2021)”, provides an in-depth analysis of the developed region pulmonary embolism diagnostic market by value, by volume (number of patients), by segments, etc. The report provides an analysis of the developed regions such as Canada, Australia and Europe on the basis of diagnostics penetration and the regions such as the US with an addressable market opportunity for the diagnostics penetration. Complete report on Pulmonary Embolism Diagnostic industry spread across 75 pages with providing 4 company Profiles, 3 tables and 31 figures is now available at http://www.marketreportsonline.com/585820.html. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the pulmonary embolism diagnostics market has also been forecasted for the period 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The competition in the pulmonary embolism diagnostic market, especially V/Q scan is dominated by one big player at global level, Cyclopharm and at regional level, in the US, the competition is dominated by Lantheus Holdings, Inc. (Xe-133). Further, key players of the global pulmonary thromboembolism diagnostic market Cyclopharm, Philips, Siemens and Jubilant LifeSciences Limited are also profiled with their financial information and respective business strategies. Country Coverage of Pulmonary Embolism Diagnostic Market: Developed Regions (Canada, Europe, Australia and Parts of Asia) & US Venous Thromboembolism (VTE) is a type of blood clot that starts in the vein. Most commonly VTE starts in the legs of the patient, however, it could occur in any other part of the body also. There are two types of VTE: Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). The pulmonary embolism generally occurs due to DVTs or pelvic vein thrombosis. Purchase a copy of this “Global Pulmonary Embolism Diagnostics Market” research report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=585820. Pulmonary embolism is a condition where the clot that is formed deep into the veins of the patient legs (or in any other body part) breaks off and travels through the bloodstream to the lungs. The clot has a tendency to block a blood vessel in the lungs and hence damage them. Pulmonary embolism is not a disease rather it is a complication of underlying VTE. There are several risk factors for pulmonary embolism such as cancer, obesity, sedentary lifestyle, age factor, major surgery, genetic blood clotting disorder or fracture of the hip or leg, etc. The onset of pulmonary embolism is depicted by shortness of breath, sudden chest pain and coughing blood. These symptoms are then followed by other symptoms such as flank pain, wheezing, cardiac murmur, etc. There are different types of tests done to detect pulmonary embolism, however, Computed Tomography Pulmonary Angiogram (CTPA) is the gold standard for detecting pulmonary embolism. Another alternative test done to detect pulmonary embolism is Ventilation-Perfusion (V/Q) Scanning. The global pulmonary embolism diagnostics market is anticipated to increase at a significant CAGR during the years 2017-2021. The pulmonary embolism diagnostic market is expected to increase due to growth in number of cancer patients, aging population, increase in per-capita healthcare expenditure, etc. Yet the market faces some challenges such as, prohibition of Technegas (an agent of V/Q Scan) in the US and introduction of Novel Oral anticoagulants. Since prevention is better than cure, a healthy lifestyle is most commonly prescribed to prevent pulmonary embolism. However, pulmonary embolism is managed majorly through intake of anticoagulants, thrombolytics, vena cava filter and compression stockings. Few Points from List of Tables & Figures: Table 1: The US Pulmonary Embolism Diagnostic Technegas Addressable Market; 2015 Table 2: Mo99 Isotope Cost Savings for the End-User Table 3: Global Players in Pulmonary Embolism Market: A Financial; 2016 Figure 1: Types of Venous Thromboembolism (VTE) Figure 2: Risk Factors of Pulmonary Embolism Figure 3: Prominent Symptoms of Pulmonary Embolism Figure 4: Other Symptoms of Pulmonary Embolism Figure 5: Physical Signs of Pulmonary Embolism Figure 6: Laboratory Tests for Pulmonary Embolism Figure 7: Types of Gaseous Radionuclides in V/Q Scan Figure 8: Management of Pulmonary Embolism Figure 9: Prevention of Pulmonary Embolism Figure 10: Developed Region Pulmonary Embolism Diagnostic Market by Value; 2015-2021 (US$ Million) Explore more Pharmaceuticals market research as well as other newly published reports by Daedal Research at http://www.marketreportsonline.com/publisher/daedal-research-market-research.html. For more information, please visit http://www.marketreportsonline.com/contacts/purchase.php?name=585820


Le V.S.,Cyclopharm Ltd. | Do Z.P.-H.,Medical Isotope Techniques MEDISOTEC | Le M.K.,Medical Isotope Techniques MEDISOTEC | Le V.,Medical Isotope Techniques MEDISOTEC | Le N.N.-T.,Medical Isotope Techniques MEDISOTEC
Molecules | Year: 2014

Methods of increasing the performance of radionuclide generators used in nuclear medicine radiotherapy and SPECT/PET imaging were developed and detailed for 99Mo/99mTc and 68Ge/68Ga radionuclide generators as the cases. Optimisation methods of the daughter nuclide build-up versus stand-by time and/or specific activity using mean progress functions were developed for increasing the performance of radionuclide generators. As a result of this optimisation, the separation of the daughter nuclide from its parent one should be performed at a defined optimal time to avoid the deterioration in specific activity of the daughter nuclide and wasting stand-by time of the generator, while the daughter nuclide yield is maintained to a reasonably high extent. A new characteristic parameter of the formation-decay kinetics of parent/daughter nuclide system was found and effectively used in the practice of the generator production and utilisation. A method of "early elution schedule" was also developed for increasing the daughter nuclide production yield and specific radioactivity, thus saving the cost of the generator and improving the quality of the daughter radionuclide solution. These newly developed optimisation methods in combination with an integrated elution-purification-concentration system of radionuclide generators recently developed is the most suitable way to operate the generator effectively on the basis of economic use and improvement of purposely suitable quality and specific activity of the produced daughter radionuclides. All these features benefit the economic use of the generator, the improved quality of labelling/scan, and the lowered cost of nuclear medicine procedure. Besides, a new method of quality control protocol set-up for post-delivery test of radionuclidic purity has been developed based on the relationship between gamma ray spectrometric detection limit, required limit of impure radionuclide activity and its measurement certainty with respect to optimising decay/measurement time and product sample activity used for QC quality control. The optimisation ensures a certainty of measurement of the specific impure radionuclide and avoids wasting the useful amount of valuable purified/concentrated daughter nuclide product. This process is important for the spectrometric measurement of very low activity of impure radionuclide contamination in the radioisotope products of much higher activity used in medical imaging and targeted radiotherapy. © 2014 by the authors.


Methods of increasing the performance of radionuclide generators used in nuclear medicine radiotherapy and SPECT/PET imaging were developed and detailed for 99Mo/99mTc and 68Ge/68Ga radionuclide generators as the cases. Optimisation methods of the daughter nuclide build-up versus stand-by time and/or specific activity using mean progress functions were developed for increasing the performance of radionuclide generators. As a result of this optimisation, the separation of the daughter nuclide from its parent one should be performed at a defined optimal time to avoid the deterioration in specific activity of the daughter nuclide and wasting stand-by time of the generator, while the daughter nuclide yield is maintained to a reasonably high extent. A new characteristic parameter of the formation-decay kinetics of parent/daughter nuclide system was found and effectively used in the practice of the generator production and utilisation. A method of early elution schedule was also developed for increasing the daughter nuclide production yield and specific radioactivity, thus saving the cost of the generator and improving the quality of the daughter radionuclide solution. These newly developed optimisation methods in combination with an integrated elution-purification-concentration system of radionuclide generators recently developed is the most suitable way to operate the generator effectively on the basis of economic use and improvement of purposely suitable quality and specific activity of the produced daughter radionuclides. All these features benefit the economic use of the generator, the improved quality of labelling/scan, and the lowered cost of nuclear medicine procedure. Besides, a new method of quality control protocol set-up for post-delivery test of radionuclidic purity has been developed based on the relationship between gamma ray spectrometric detection limit, required limit of impure radionuclide activity and its measurement certainty with respect to optimising decay/measurement time and product sample activity used for QC quality control. The optimisation ensures a certainty of measurement of the specific impure radionuclide and avoids wasting the useful amount of valuable purified/concentrated daughter nuclide product. This process is important for the spectrometric measurement of very low activity of impure radionuclide contamination in the radioisotope products of much higher activity used in medical imaging and targeted radiotherapy.


Le V.S.,Cyclopharm Ltd | Morcos N.,Cyclopharm Ltd | Bogulski Z.,Cyclopharm Ltd
Journal of Radioanalytical and Nuclear Chemistry | Year: 2014

A self-shielded, sterile and cartridge-based radioisotope concentrator device coupled to 99mTc/188Re generators to increase the 99mTc/188Re-concentration of the generator eluate was developed based on new aminoalkyl-functionalized silica sorbent which conditionally catches and release 99mTc/188Re to concentrate the daughter nuclide of the generator eluates. The cartridge can be used for multiple elutions with an overall concentration factor of >100 and daughter nuclide recovery yield of >85 %. This device can be used for 10 days extension of 99mTc-generator life-time, saving about 20 % of the generator activity and for "early" generator-elution programs, under which the generator is eluted at an optimized build-up time for increasing the effectiveness of 99mTc/99Mo utilisation. © 2014 Akadémiai Kiadó, Budapest, Hungary.


Patent
Cyclopharm Ltd | Date: 2013-10-25

A system using a radioisotope concentrator device comprising a body having at least one injection port and at least one valve being configurable between a first open configuration for allowing fluid communication between the at least one injection port and the concentrator column and a second open configuration to prevent fluid communication between the at least one injection port and the concentrator column in use, the system further comprising an injection device comprising an eluent for eluting through the concentrator column via the at least one injection port when the at least one valve of the radioisotope concentrator device is in a selected open configuration in use.

Loading Cyclopharm Ltd. collaborators
Loading Cyclopharm Ltd. collaborators